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Abstract
Toll-like receptor (TLR) 2, a type I membrane receptor that plays a key role in innate
immunity, recognizes conserved molecules in pathogens, and triggering an
inflammatory response. It has been associated with inflammatory and autoimmune
diseases. Soluble TLR2 (sTLR2) variants have been identified in human body
fluids, and the TLR2 ectodomain can negatively regulate TLR2 activation by
behaving as a decoy receptor. sTLR2 generation does not involve alternative
splicing mechanisms, indicating that this process might involve a post-translational
modification of the full-length receptor; however, the specific mechanism has not
been studied. Using CD14+ peripheral human monocytes and the THP-1 monocytic
leukemia-derived cell line, we confirm that sTLR2 generation increases upon
treatment with pro-inflammatory agents and requires a post-translational
mechanism. We also find that the constitutive and ligand-induced release of sTLR2
is sensitive to pharmacological metalloproteinase activator and inhibitors leading us
to conclude that metalloproteinase TLR2 shedding contributes to soluble receptor
production. By expressing human TLR2 in ADAM10- or ADAM17-deficient MEF
cells, we find both enzymes to be implicated in TLR2 ectodomain shedding.
Moreover, using a deletion mutant of the TLR2 juxtamembrane region, we
demonstrate that this domain is required for sTLR2 generation. Functional analysis
suggests that sTLR2 generated by metalloproteinase activation inhibitsTLR2-
induced cytokine production by this monocytic leukemia-derived cell line. The
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identification of the mechanisms involved in regulating the availability of soluble
TLR2 ectodomain and cell surface receptors may contribute further research on
TLR2-mediated processes in innate immunity and inflammatory disorders.
Introduction
The innate immune system is essential for inducing an inflammatory response and
for the activation of acquired immunity [1]. Toll-like receptors (TLRs) are a class
of pattern recognition receptors (PRRs) that play a key role in innate immunity
and trigger a specific immune response. TLRs are expressed predominantly in
immune cells and recognize conserved structures from pathogenic (PAMPs -
pathogen-associated molecular patterns-) and non-pathogenic microorganisms or
endogenous ligands associated with cellular damage (DAMPs-damage associated
molecular patterns-). TLRs lead to activation of transcription factors, such as NF-
kB, AP-1 and IRF3, which induce the expression of cytokines, chemokines and
adhesion molecules, among others. In humans, 10 TLRs have been described that
recognize PAMPs/DAMPs of various chemical natures [2, 3]. TLR2 is a type I
integral membrane protein that, upon recognition of PAMPs from bacteria, fungi
and viruses as well as DAMPs, forms a homodimer or heterodimer with either
TLR1 or TLR6 [3].
In addition to the role of TLRs in activating the immune response against
pathogens, members of this receptor family have also been associated with
inflammatory and autoimmune diseases [4], suggesting that TLR-signaling
pathways must be tightly regulated to avoid harmful inflammatory responses
[5, 6]. TLR-activation can be regulated by cytoplasmatic molecules, such as
MyD88s, IRAK-M, TOLLIP and by activation of the PI3K/Akt pathway
[7, 8, 9, 10]. Additionally, there is a negative regulatory function for the
ectodomain of TLRs, as has been demonstrated for the soluble form of
murineTLR4, a splicing variant of tlr4 gene [11], the soluble TLR5 identified in
fish [12] and soluble forms of human TLR2 (sTLR2) [13] and TLR9 [14].
Furthermore, sTLR2 has been detected in human fluids, such as plasma, breast
milk, saliva and amniotic fluid as well as in supernatant of cultured monocytes
[13, 15, 16]. sTLR2 functions as a regulator of TLR2 responses, playing a role as a
decoy receptor and interfering with TLR2 mobilization to lipid rafts and
association with co-receptor CD14 [13, 17]. In pathological conditions, such as
inflammatory bowel diseases, HIV infection and acute myocardial infarction,
sTLR2 levels are altered when compared to healthy subjects [18, 19, 20].
It has been suggested that sTLR2 generation involves a post-translational
mechanism of the full-length receptor [13] as only one encoding TLR2 mRNA has
been detected, excluding the contribution of alternative splicing [13, 21].
However, the specific post-translation mechanism for sTLR2 production has not
been studied.
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Proteolytic cleavage of transmembrane proteins is a common post-translational
mechanism. When this process occurs at the ectodomain level, releasing a soluble
fragment, it is referred as ectodomain shedding. Matrix metalloproteinases
(MMPs) and disintegrinmetalloproteinases (ADAMs) are broadly studied
enzymes that participate in ectodomain shedding [22, 23]. In the immune system,
this mechanism is essential for generating soluble biologically active molecules,
such as cytokines and their receptors, chemokines and growth factors. This
process also produces a membrane-bound protein fragment which typically
undergoes regulated intramembrane proteolysis (RIP), involving the c-secretase
complex [22]. In this study, we explore in monocytic cells that TLR2 proteolytic
processing and sTLR2 generation triggered by Pam3CSK4, aTLR2-specific ligand.
We now report that sTLR2 production, involving ADAM10- and ADAM17-
dependent TLR2-ectodomain shedding contributes to soluble receptor generation
in MEF cells and that the juxtamembrane domain of TLR2 is required for efficient
cleavage. These results suggest that sTLR2, induced by metalloproteinase
activation, functions as a negative regulator of the TLR2-induced cytokine
production.
Materials and Methods
Ethics Statement
All clinical investigation must have been conducted according to Declaration of
Helsinki principles. Participants were identified by number, not by name, and
provided informed consent. The study was approved by the Institutional Review
Board at Clı´nica Las Condes.
Isolation of human peripheral blood CD14+ cells
Human peripheral blood CD14+ cells were obtained from healthy donors by
negative selection using a commercially kit (RosetteSep, StemCell), following
manufacturer’s instructions. Briefly, EDTA was added to whole blood to a final
concentration of 1 mM and 50 mL of RosetteSep Human Monocyte Enrichment
Cocktail per mL; the sample was gently mixed, incubated for 20 min and then
diluted with an equal volume of PBS containing 2% FBS/1 mM EDTA, followed
by Ficoll-Hypaque (GE Healthcare) density-gradient centrifugation. Cells at the
interface were collected, washed and plated in RPMI medium. Cell viability and
CD14 content were analyzed by flow cytometry (BD FACSCalibur). Purified cells
were 76–85% CD14+ and 91–97% viable.
Cell culture
Isolated human peripheral blood CD14+ cells and the human acute monocytic
leukemia-derived cell line, THP-1 (American Type Culture Collection, ATCC)
were cultured in RPMI 1640 (Gibco, Invitrogen). HEK293 cells were also from
ATCC and cultured in Dulbecco’s modified Eagle medium (DMEM, Gibco,
TLR2 Ectodomain Shedding
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Invitrogen). HEK293cells stably expressing human TLR2-yellow fluorescent
protein (TLR2-YFP), kindly provided by D. Golenbock [24], were cultured in
DMEM medium with 0.5 mg/mL G418 (Sigma-Aldrich). Mouse embryonic
fibroblast (MEF) ADAM17-/- cells were provided by Amgen, USA; ADAM10-/-
[25] and wild type MEF by VIB Institute, Belgium and cultured in DMEM/F12
medium. All culture media were supplemented with penicillin/streptomycin
(Gibco, Invitrogen), 10% heat-inactivated fetal calf serum (Gibco, Invitrogen).
Cells were maintained at 37 C˚, 5% CO2.
Chemicals reagents
The pharmacological activator and inhibitor of metalloproteinase APMA, and
TAPI-1, respectively, were purchased from Biomol International. GM6001 was
purchased from Chemicon International Inc., USA. PMA, cycloheximide, EDTA,
DAPT and E. coli LPS were obtained from Sigma-Aldrich; TLR2-ligand Pam3CSK4
was purchased from Enzo Life Science. rhTLR2 was obtained from R&D Systems,
USA. GI254023X was kindly provided by A. Ludwig (Universita¨tklinikum
Aachem, Germany).
Cell culture supernatants for sTLR2 detection
For sTLR2 analysis in conditioned media, THP-1 cells were washed with serum-
free medium and 16106 cells/mL cultured in serum-free RPMI1640 medium
supplemented with penicillin/streptomycin in 6-well plates. After incubation, cell
supernatants were processed as described in [13]. Briefly, the supernatants were
centrifuged for 5 min at 1200 rpmandfiltered (0.22 mm pore); 0.1% (v/v) Nonidet
P-40 and protease inhibitors were added and concentrated 10–15 times
(Centricon YM-10 concentrators; Millipore) before Western blotting or ELISA.
Serial dilutions of the cell homogenates were performed and the detection of
antigen was linear in the range of concentration studied.
Isolated peripheral CD14+ cells were incubated, for the stimulation time
periods, in serum-free RPMI1640 medium; cell supernatant was collected and
centrifuged at 14000 rpm for 10 min before ELISA assay.
TransientlyTLR2-YFP-transfected HEK293Tor MEF cells were incubated in
serum-free medium supplemented with penicillin/streptomycin; cell supernatants
were processed and concentrated 10 times as described above.
Cell viability analysis
Cell counts and viability were determined using a hemocytometer and trypan blue
dye exclusion as well as with propidium iodide exclusion method using a flow
cytometry (BD FACSCalibur analyzer).
TLR2 Ectodomain Shedding
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Quantification of TLR2, IL-8, TNF-a level in cell supernatant
To eliminate contamination with cellular debris, supernatants were carefully
processed by centrifugation at 14000 rpm and filtered through 0.22 mm pore
filters. TLR2 levels were determined using a commercial enzyme-linked
immunosorbent assay (ELISA) kit (DuoSet, R&D Systems). The final sTLR2
content in conditioned media was calculated, adjusting for the concentration
factor.
Levels of IL-8 and TNF-a were also determined by ELISA (R&D Systems,
eBioscience, respectively). All samples were analyzed in duplicate according to the
manufacturer’s instructions.
Flow cytometric analysis
Specific antibodies against human TLR2, CD14 and isotype-matched control
antibodies were purchased from eBioscience. For analysis of cell surface TLR2 or
CD14, 36105 freshly isolated cells were suspended in PBS containing 10% human
AB plasma, washed and incubated with anti-human FITC- or PE-conjugated
TLR2 antibodies, anti-humanPerCP-Cy5.5 conjugated CD14 antibodies or
isotype-matched antibodies for 30 min on ice. After washing, cells were fixed in
2% paraformaldehyde. Cell-surface fluorescence intensity was assessed using a
FACSCalibur analyzer and CellQuest software (BD Biosciences).
Cell transfection
TLR2-YFP (kindly provided by D. Golenbock, UMass Medical School, USA) and
mutant constructs were transfected in HEK293T cells with FuGENE reagent
(Roche) according to the manufacturer’s protocol. Briefly, FuGENE reagent (3 mL
per mg of transfected plasmid) was added to OPTIMEM (Gibco, Life
Technologies) with the purified plasmid DNA and allowed to incubate for 40 min
at room temperature before adding to cells plated in OPTIMEM. After 24 h, the
transfection medium was replaced.
MEFs were transfected with Lipofectamine 2000 (Invitrogen, Life
Technologies). The medium was replaced 6 h post-transfection. To normalize
transfection efficiency in MEF cells soluble variant release levels were expressed as
the ratio of sTLR2 levels in the cell culture supernatants and TLR2 in cell
homogenates in ELISA assays and adjusted to the total protein content in cell
homogenates by Bradford method.
Immunoblotting
Cells were lysed with ice-cold Low Detergent Buffer (LDB) supplemented with
Complete Mini Protease Inhibitor Cocktail tablets (Roche Applied Science)and
disrupted by sonication three times for 10 seconds at 14 Watts on ice. The samples
were centrifuged at 14000 rpm for 5 min to ensure against any cellular
contamination in the supernatant. Protein concentration was determined by
TLR2 Ectodomain Shedding
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Bradford assay (BioRad). Equivalent amounts of total protein were separated
using 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis and
electrotransferred to a nitrocellulose membrane (BioRad). Non-specific binding
was blocked with a solution containing 5% non-fat milk in TBS (2 mM Tris-HCl,
pH 7.6, 13.7 mM NaCl) by agitation for 1 h at room temperature.
Detection of TLR2 was determined with a polyclonal anti-TLR2 (N-terminal)
antibody (R&D System). Recombinant human TLR2 extracellular region
(rhTLR2) was included in a lane in the gel to indicate the identity of the receptor.
The specificity of the detection was confirmed by performing peptide competition
assay by co-incubation of the TLR2 antibody with the rhTLR2.
Detection of TLR2-YFP was determined using an anti-GFP antibody (Abcam)
followed by a goat antibody raised against rabbit IgG and conjugated to
horseradish peroxidase (HRP) (Jackson ImmunoResearch Laboratories). Actin
content was also detected with a specific antibody (Sigma-Aldrich).
Immunoreactive bands were visualized with the enhanced chemiluminescence
(ECL) Western Blotting System (Amersham).
Negative regulation assay
THP-1 cells (56105 /well) were cultured in 500 mL of serum free RPMI medium
and pre-incubated for 30 min with 100 mL of 10x concentrated medium of APMA
treated or untreated-HEK293-TLR2-YFP, or mock-transfected HEK293. Cells
were stimulated with Pam3CSK4 (10 ng/mL) or not (control) for 6 h, and
supernatants were collected, centrifuged at 14000 rpm for 10 min and assayed for
IL-8 detection by ELISA.
Statistical analysis
Statistical analysis was performed by Student’s t-test using GraphPad Prism 5
software. The lacks of probability are indicated.
Results
Production of sTLR2 by THP-1 cells occurs post-translationally
Generation of sTLR2 can result from the post-translation modification of
membrane-associated TLR2 [13]. As monocytes express high levels of membrane
TLR2 and also produce sTLR2 [13], we initially examined the release of sTLR2
into culture supernatant of the acute monocytic leukemia-derived cell line, THP-
1, by ELISA. Here, we show that constitutive sTLR2 levels did not decrease, but
ligand-stimulated sTLR2 indeed increased in the presence of the translation
inhibitor cycloheximide (Fig. 1A). More than 90% of the cells excluded trypan
blue, eliminating the possibility that the treatment induced cell death. Concordant
with Dulay, A. et al. [16], sTLR2 levels in culture supernatant increased with
cycloheximide treatment. This result reveals that sTLR2 production involves a
post-translation mechanism that may not require alternative splicing.
TLR2 Ectodomain Shedding
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The presence of sTLR2 in THP-1 culture supernatant was determined by
Westernblot analysis, using an anti-TLR2 ectodomain antibody, which revealed
two major specific bands of ,73–75 kDa, with a migration pattern similar to that
of recombinant TLR2 (rhTLR2) in reducing conditions (75–80 kDa) (Fig. 1B),
suggesting that these bands correspond to the TLR2 ectodomain. Although
additional experiments are required to reach a final conclusion, the two
immunoreactive bands can correspond to glycosylated sTLR2 polypeptides with
slightly different electrophoretic mobility, as was previously described [26]. The
,102 kDa TLR2 band corresponds to the full-length receptor, consistent with the
molecular weight previously reported for the full-size TLR2 glycoprotein [27].
Similar results for the full-length TLR2 were also previously obtained by using
freshly isolated monocytes lysates [13].
Fig. 1. Production of sTLR2 involves a post-translation mechanism. (A) THP-1 cells were pretreated or
not with cycloheximide (100 mg/mL) for 30 min and stimulated with Pam3CSK4 (1 mg/mL) for 5 h and the
amount of sTLR2 was quantified in the cell culture supernatants by ELISA. Student t test, * p,0.05. (B)
Detection of sTLR2 in 18 h culture supernatant (SN) of THP-1 cells by Western blotting using a N-terminal
anti-TLR2 antibody. One representative of three experiments is shown. SN: cell culture supernatant; rhTLR2:
recombinant human TLR2 protein. (C) Cell surface TLR2 levels evaluated by flow cytometry after stimulation
with Pam3CSK4 (1, 10 or 20 mg/mL) for 2 h. ***, p,0.0001. (D) Cell surface TLR2 levels evaluated by flow
cytometry after treatment with cycloheximide and then stimulation for 2 h with Pam3CSK4. MFI5 mean
fluorescence intensity. *, p,0.05; **, p50.009.
doi:10.1371/journal.pone.0104624.g001
TLR2 Ectodomain Shedding
PLOS ONE | DOI:10.1371/journal.pone.0104624 December 22, 2014 7 / 20
Addition of Pam3CSK4 alone augmented the levels of membrane-associated
TLR2 (Fig. 1C), as was previously reported [28]. To understand the post-
translational mechanism involved in sTLR2 production, the levels of membrane-
associated TLR2 were determined in Pam3CSK4–stimulated cells that have been
pre-treated with cycloheximide. A significant decrease in membrane-associated
TLR2 was observed after 2 h (Fig. 1D).
These results demonstrate that in the absence of de novo protein synthesis,
receptor level decreases in plasma membrane. This effect may be due to TLR2
shedding, although these data do not rule out other mechanisms that could
reduce surface receptor levels, such as endocytosis. However, our observations
suggest the occurrence of membrane TLR2 decrease and TLR2 de novo synthesis,
simultaneously.
Then, the effect of pro- and anti-inflammatory molecules on sTLR2 production
was studied. Cell treatment with phorbol ester (PMA) or Pam3CSK4, known
activators of metalloproteinases [29, 30], induced and increased in sTLR2
production in a time-dependent manner (S1A Fig.), which is consistent with
previous reports [13]. sTLR2 was constitutively produced by THP-1. Pam3CSK4
also increased sTLR2 production from isolated human peripheral CD14+ cells
(S1B Fig.). Moreover, when THP-1cells were stimulated with LPS, a TLR4 ligand,
production of sTLR2 also increased (S1C Fig.), suggesting that broad pro-
inflammatory stimuli promote production of the soluble receptor.
When levels of membrane-associated TLR2 were determined in PMA-treated
THP-1 cells, a significant decrease was seen, even after a short stimulation period
of 30 min, and this decrease was maintained up to 120 min (S1D Fig.). Reduced
membrane TLR2 levels in cells exposed to PMA treatment may be produced by a
TLR2 metalloproteinase shedding mechanism. In contrast, Pam3CSK4 treatment
increases TLR2 levels on the cell surface, confirming the previously described
observations by Li, CH et al. [28]. These results suggest that different mechanisms
occur simultaneously: TLR2 ectodomain shedding, and de novo expression of
TLR2. PMA, compared to TLR2 agonists, is widely known for its strong effect on
activation of several intracellular signaling pathways that converge in the
induction of metalloproteinases.
Based on previous results indicating that the anti-inflammatory agent
dexamethasone did not counteract Pam3CSK4-induced TNF-a expression [10],
sTLR2 production was analyzed in cells exposed to both stimuli. We found that
dexamethasone did not decrease ligand-inducedsTLR2 generation (S1E Fig.).
Constitutive and ligand-induced sTLR2 production involves
metalloproteinase-dependent TLR2shedding in human monocytes
Ectodomain shedding of immune-related molecules, such as TNF-a and its
receptors, occurs from the surface of leukocytes by the effect of metalloproteinases
[31]. As shown above, PMA and Pam3CSK4 increase sTLR2 levels. Both agents are
known to induce metalloproteinase activation [32, 33]. To test whether or not
metalloproteinases are involved in constitutive and ligand-induced sTLR2
TLR2 Ectodomain Shedding
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production in THP-1 cells, we stimulated with p-aminophenylmercury acetate
(APMA), a broad metalloproteinase activator. We found that APMA promoted an
increase in sTLR2 concentration (Fig. 2A) and, as expected, a decrease in
membrane-associated TLR2 levels (Fig. 2B and right histogram), with no changes
in viable cell count (data not shown). Similarly, shedding of TNF-a was also
observed in cells stimulated with APMA, reflected by its increased level in cell
culture supernatants, as well as by its decreased content in the cell surface (data
Fig. 2. Metalloproteinase activity regulates sTLR2 release and TLR2 surface content from THP-1 cells. (A) Cells were treated with APMA (10 mM),
vehicle (DMSO) or left untreated (-) for 5 h and the concentration of sTLR2 in the supernatants was determined by ELISA. Student t-test, **, p50.003. (B)
Cell surface TLR2 was examined on these cells after 2 h addition of APMA (10 mM), vehicle (DMSO) or left untreated (-) using anti-TLR2-FITC conjugated
antibody and analysis by flow cytometry. ***, p,0.0001. MFI5 mean fluorescence intensity. A representative histogram is shown using cells stained with
isotype control antibody (filled histogram), untreated cells (dot line) and APMA-treated cells (black line). (C) Cells were treated for 18 h with EDTA (2 mM),
TAPI-1 (25 mM or 75 mM), GI254023X (5 mM) (GI) or left untreated (-) and the sTLR2 concentration in the cell supernatants was determined by ELISA.
*, p,0.05; **, p50.003. Westernblot (10% SDS-PAGE reducing gel) shows sTLR2 release in cell supernatant of TAPI-1 or left untreated (-) treated THP-1
cells using N-terminal anti-TLR2 antibody. One representative of three experiments is shown. (D) Cells treated with TAPI-1 (25 mM or 75 mM), GI254023X
(GI) (5 mM) or left untreated (-) were added 30 min prior to cell stimulation with Pam3CSK4 (1 mg/mL) for 18 h and the concentration of sTLR2 in cell
supernatants was assayed by ELISA. Data represent the mean ¡ SE of three independent determinations. Student t test **, p50.001; ***, p50.0001.
doi:10.1371/journal.pone.0104624.g002
TLR2 Ectodomain Shedding
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not shown). These results suggest that a proteolytic cleavage of membrane-
associated TLR2 could be implicated in the mechanism of sTLR2 generation.
To confirm the participation of a metalloproteinase, pharmacological
inhibition of constitutive sTLR2 production was assessed initially using EDTA
(2 mM), a chelator of divalent ions, necessary for metalloproteinase cleavage. A
significant decrease in sTLR2 concentration in the supernatant was observed
(Fig. 2C), suggestive that MMPs may be participating in TLR2 shedding, thus
supporting the use of other pharmacological strategies. Accordingly, similar
results were obtained with the broad-spectrum metalloproteinase inhibitor, TAPI-
1, showing a decrease in sTLR2 content (Fig. 2C). An inhibition curve of basal
sTLR2 release was made with TAPI-1, and we use the concentration where the
cells were metabolically active and not undergoing cell death (less than 5% tripan-
blue positive cells in the culture) (data not shown). These results indicate that
metalloproteinase activity can contribute to constitutive sTLR2 generation,
however they cannot rule out that other mechanisms may be participating in the
soluble receptor production.
Treatment with TAPI-1 shown a diminution in sTLR2 production (Fig. 2C) as
detected by western blotting using an N-terminal anti-TLR2 antibody. The two
bands of ,73 and 75 kDa have similar molecular size to the recombinant TLR2
ectodomain (see also Fig. 1B). A less intense TLR2 immunoreactive band of
,100 kDa was also observed that might correspond to the full-length TLR2 [27]
associated to membrane vesicles.
To define whether sTLR2 release by metalloproteinase activity is a ligand-
dependent mechanism, we determined the effect of TAPI-1 on cells challenged
with Pam3CSK4 and a significantly reduction of sTLR2 production was observed
(Fig. 2D), with no changes in viable cell count (data not shown). Similarly, TAPI-
1 inhibits constitutive and TLR2-mediated production of TNF-a, reflected by
decreased levels in cell culture supernatants (data not shown). These results
confirm the involvement of members of the metalloproteinase subfamily in the
TLR2-driven sTLR2 generation. Despite the fact that metalloproteinase shedding
participates in sTLR2 production, we cannot rule out other complementary
mechanism for its generation in particular considering that TAPI-1 inhibited
sTLR2 production in resting cells by ,30%.
In order to determine whether a specific metalloproteinase could be implicated
in TLR2 shedding, we used a pharmacological inhibitor with selectivity for
ADAM10, GI254023X [34]. No effect of GI254023X was observed on constitutive
sTLR2 production (Fig. 2C); in contrast, decreased Pam3CSK4-induced sTLR2
content was observed (Fig. 2D), no change in viable cell count was observed (data
not shown). This result demonstrates that TLR2 cleavage induced by the receptor
ligand was dependent on the activity of ADAM10 in THP-1 cells; although this
observation cannot exclude the involvement of other metalloproteinases.
To confirm that constitutive and ligand-induced sTLR2 production involves
metalloproteinase-dependent TLR2 shedding in monocytes, isolated human
peripheral CD14+ cells were stimulated with APMA or pharmacological
metalloproteinase inhibitors. TNF-a levels in supernatant were also quantified by
TLR2 Ectodomain Shedding
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ELISA. TAPI-1 and GM6001 inhibit constitutive and TLR2-mediated production
of TNF-a (data not shown). Accordingly to assays with THP-1 cell line,
metalloproteinase activator increase sTLR2 production (Fig. 3A).
Metalloproteinase inhibitors, TAPI-1 and GM6001, decreased constitutive
(Fig. 3B) and Pam3CSK4-induced (Fig. 3C) sTLR2 generation, confirming that
TLR2 shedding is involved in soluble receptor generation in human monocytes.
ADAM10- and ADAM17-mediated TLR2 shedding
The participation of ADAM10 and ADAM17 in TLR2 ectodomain shedding was
further investigated using MEFs generated from ADAM10- and ADAM17-
deficient mice. Release of sTLR2 was significantly reduced in ADAM10- and
ADAM17-deficient MEF cells transiently expressing human TLR2 (Fig. 4),
demonstrating that these two enzymes can contribute to TLR2 shedding. If this is
the case, i.e. that both ADAM 10 and ADAM17 are involved in TLR2 shedding,
our results suggest that, in the absence of one of them, the other compensate and
induce TLR2 shedding. Several studies have shown that in the absence of one
enzyme in deficient-cell or animal models, a different, non-canonical enzyme can
substitute for its function and act on the substrate [35]. Therefore, our studies
cannot exclude other enzymes and/or other mechanisms participating in sTLR2
generation in MEF cells.
The content of sTLR2 in conditioned media of TLR2-transfected MEF cells
stimulated with Pam3CSK4 was not detected. Indeed, over 60% of cell did not
survive this treatment as detected by trypan-blue exclusion (data not shown). This
result could be due to a greater susceptibility of TLR2-expressing ADAM10-/- or
ADAM17-/- MEFs cells to undergo apoptosis when exposed to Pam3CSK4. As
Fig. 3. TLR2 shedding is involved in sTLR2 generation in human peripheral monocytes. (A) Isolated human peripheral CD14+ cells were treated with
APMA (10 mM), vehicle (DMSO) or left untreated (-) for 5 h. *, p,0.05. (B) Cells were incubated for 18 h with TAPI-1 (25 mM or 75 mM), GM6001 (10 mM) or
left untreated (-).*, p,0.05.(C) Cells treated with TAPI-1 (25 mM or 75 mM), GI254023X (GI) (5 mM) or left untreated (-) were added 30 min prior to cell
stimulation with Pam3CSK4 (1 mg/mL) for 18 h. Supernatants were harvested and soluble receptor was measured by ELISA. *, p,0.05; ** p,0.01. Data are
express as percentage of maximal release ¡ SE of two independent determinations using four different healthy donors.
doi:10.1371/journal.pone.0104624.g003
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reported previously, Pam3CSK4 activates a cellular death pathway via TLR2, and
probably the lack of function of a shedding mechanism might impact on sTLR2
generation controlling TLR2-induced apoptosis [36].
Deletion in TLR2 juxtamembrane region impairs sTLR2 production
Although there is no consensus amino acid sequence for proteolytic cleavage by
metalloproteinases; most transmembrane proteins that are susceptible to
metalloproteinase shedding are cleaved at the juxtamembrane region [23]. To
evaluate the potential cleavage site of metalloproteinase(s) in TLR2, we generated
two juxtamembrane-region deletion-mutants, of 10 (TLR2-YFP-D10) and 16
(TLR2-YFP-D16) amino acids, respectively, corresponding to the sequence
between the last TLR2 leucine-rich-repeat (LRR) motif and the transmembrane
region (Fig. 5A). Control (TLR2-YFP) and mutant constructs were transiently
transfected into HEK293T cells that do not endogenously express TLR2. The
TLR2 surface content, evaluated by flow cytometry, was similar inTLR2-YFP and
TLR2-YFP-D10, but was significantly decreased in TLR2-YFP-D16 (Fig. 5B), even
though theTLR2 content in whole cell lysates of the mutants was similar (Fig. 5C).
The ,110 kDa band in the Westernblot corresponds to TLR2-YFP, which is
absent in the lysate of TLR2-YFP (-) cells. The ,80 kDa band could correspond
to a fusion protein (TLR2-YFP), albeit with a different degree of glycosylation.
Whereas YFP is fused to the TLR2 C-terminus, the ,80 kDa band does not
correspond to the TLR2 ectodomain of closest electrophoretic mobility (see
Fig. 1B), because upon MMPs shedding it lacks the YFP-tag.
These findings suggests that removal of 16 amino acids from the TLR2
juxtamembrane region affects TLR2 cell membrane expression, as has been shown
Fig. 4. ADAM10 and ADAM17 are involved in TLR2 shedding. MEF cells were transfected with an
expression plasmid encoding human TLR2 or with an empty vector; sTLR2 content in cell supernatants was
analyzed by ELISA. sTLR2 content (pg/mL) was normalized to total TLR2 cell levels (ng/mg total protein).
Data represent the mean ¡ SE of three independent determinations. *, p,0.05.
doi:10.1371/journal.pone.0104624.g004
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for juxtamembrane region deletion mutants ofMHC Class I-related chain A
(MICA) [37]. To confirm that the mutation affects membrane-anchored receptor
function, we found no increased production of IL-8 in TLR2-YFP-D16-expressing
cells stimulated with Pam3CSK4, when compared to TLR2-YFP- or TLR2-YFP-
D10-expressing cells (Fig. 5D). This protein deletion might be affecting ligand
binding to the extracellular domain that has an impact on IL-8 release (Fig. 5D).
This effect can be a consequence of a conformational change in TLR2 ectodomain,
Fig. 5. Deletion of TLR2 juxtamembrane region impairs sTLR2 generation. (A)Amino acid sequence of
wild type (TLR2-YFP) surrounding the potential TLR2 transmembrane domain and deletion mutants, lacking
10 (TLR2-YFP-D10) or 16 (TLR2-YFP-D16) amino acids. Student t test, ** p,0.01. (B) HEK293T cells were
transiently transfected with TLR2-YFP, TLR2-YFP-D10 or TLR2-YFP-D16, and TLR2 surface expression was
evaluated by flow cytometry with anti-TLR2-PE antibody. MFI5 mean fluorescence intensity. Student t test,
/>** p,0.01. () Westernblot analysis, using anti-GFP antibody, of transfected cell lysates described in (B)
Mock transfected HEK-cells (-); bands correspond to two GFP immunoreactive TLR2-YFP
polypeptides.<?FIGTITLE 0 (D) Pam3CSK4-induced IL-8 production by wild type and deletion mutant
expressing cells was evaluated by ELISA. (E) sTLR2 content in cell supernatants, relative to Pam3CSK4-
induced wild type cells, of wild type or D10 or D16 deletion mutant transfected cells was evaluated by ELISA. *
p,0.05; ** p,0.01. All graphs show mean values ¡ SE of three independent experiments.
doi:10.1371/journal.pone.0104624.g005
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leading to a decrease affinity for the ligand. However, additional studies are
needed to confirm this hypothesis.
Finally, decreased sTLR2 content in cell supernatants was determined in TLR2-
YFP-D10- and -D16-expressing cells in comparison to the wild type TLR2-YFP
(Fig. 4E), indicating that TLR2 juxtamembrane deletion affects sTLR2 generation
and that the sheddase cleavage site is located in a receptor domain close to the
transmembrane region. Another possibility is that the deletion affects the
structure of TLR2 ectodomain therefore is not recognized by the enzyme. The
effect of Pam3CSK4 on the release of sTLR2 by D10 or D16 cells was also affected
and undetectable differences with untreated cells were seen (data not shown),
since the enzyme-recognition or-cleavage site in full-length TLR2 is altered in
these mutants.
sTLR2 induced by metalloproteinase-activation inhibits
Pam3CSK4-mediated IL-8 production
To demonstrate the negative regulatory function of sTLR2, induced by
metalloproteinase activation, we analyzed the effect of conditioned media from
HEK293-TLR2-YFP cells exposed to APMA on TLR2-induced IL-8 production by
THP-1 cells. Activation of metalloproteinases in HEK293-TLR2-YFPcells induced
sTLR2 release (Fig. 6A), similar to the effects previously described (see Fig. 2A).
IL-8 production was significantly reduced when Pam3CSK4-activated THP-1 cells
were incubated with conditioned media from APMA-treated or
untreatedHEK293-TLR2-YFP cells (Fig. 6B). However, inhibition of IL-8
production was higher in cells exposed to conditioned media of APMA-treated
HEK293-TLR2-YFP cells compared with untreated HEK293-TLR2-YFP cells
conditioned media. THP-1 cells were also incubated with conditioned media from
APMA-treated or untreated HEK293, cells that do not endogenously express
TLR2 and no effect on IL-8 was observed (Fig. 6B). These data suggest that sTLR2
induced by metalloproteinase activation inhibits IL-8 production, thus acting as a
negative regulator. Similar results were obtained when the recombinant human
TLR2 ectodomain protein was used as a control to antagonize TLR2-driven IL-8
production (Fig. 6C). Although natural sTLR2 released by cells was shown to be
biologically active in negatively regulating TLR2-triggered inflammatory responses
[13], the inhibition of IL-8 production by soluble variant induced by
metalloproteinase activation has not been previously demonstrated. These results
confirm those previously reported from natural sTLR2 and extend our knowledge
about the mechanisms leading to the production of this negative regulator of
innate immune and inflammatory responses.
Discussion
In this study, we demonstrated that metalloproteinase is involved in the
mechanisms that generate constitutive and ligand-induced sTLR2 and we revealed
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the functional role of this shed receptor on TLR2-induced cytokine production.
Over-activation of TLR2 signaling is involved in multiple pathological conditions,
such as autoimmune and inflammatory diseases [38]. Therefore, regulation of
TLR2 activity and the signaling cascade represents an important mechanism for
maintaining cell homeostasis. sTLR2 has proven to be a negative regulator of the
receptor-dependent activity both in vitro and in vivo, using recombinant TLR2
ectodomain in monocyte cultures or in a mouse model of peritoneal
inflammation, respectively [13, 17]. Furthermore, levels of sTLR2 are altered in
pathological conditions, such as ulcerative colitis and acute myocardial infarction
[18, 20]. Collectively, these data suggest that soluble variants of TLR2 play an
important role in regulating the receptor activation and in mechanisms leading to
inflammatory diseases. Thus, how these pro-inflammatory conditions impact on
the mechanisms by which sTLR2 are generated is of vast interest.
The study confirms sTLR2 production is increased by activation of peripheral
monocytes and a monocytic-leukemia derived cell line with Pam3CSK4 suggesting
that TLR2 activation increases its own shedding. PMA and LPS, other potent
inflammatory stimuli, also increased production of the soluble receptor,
presumably because they converge at some level in the signaling pathway.
Moreover, the broadly used anti-inflammatory agent dexamethasone did not
decrease the ligand-induced sTLR2 generation, suggesting that the intracellular
events, perhaps including the PI3K pathway, triggered by TLR2 activation in the
presence of glucocorticoid [10], are also involved in this process.
The mechanism contributing to sTLR2 generation has not yet been completely
clarified. Inhibition of protein translation did not decrease sTLR2, demonstrating
Fig. 6. sTLR2 induced by metalloproteinase activator APMA inhibit TLR2 ligand-mediated IL-8 production. (A) Stably transfected HEK-TLR2-YFP
cells were incubated for 24 h with fresh medium; 5 h prior to cell supernatant collections they were treated with APMA (10 mM) or DMSO; and sTLR2 content
in conditioned media was determined by ELISA. Student t test ***, p,0.0001. (B) THP-1 cells were pre-treated with conditioned media of HEK293 (HEK-
WT), APMA-treated HEK293 (HEK-WT+APMA), HEK-TLR2-YFP (HEK-TLR2) or APMA-treated HEK-TLR2-YFP cells (HEK-TLR2+APMA), and then
Pam3CSK4-induced IL-8 production was determined. Student t test *, p50.0481; **, p50.0017;
##, p50.008. (C) Pam3CSK4-induced IL-8 production by
THP-1 cells, pre-treated or not with recombinant human TLR2 ectodomain. Student t test *, p,0.05. All graphs show mean values ¡ SE of three
independent experiments.
doi:10.1371/journal.pone.0104624.g006
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that the mechanism involved in sTLR2 generation is a post-translation process
and does not require alternative splicing, as was previously shown [13]. Strikingly,
cycloheximide treatment lead to an increased in sTLR2 production in cells
stimulated with Pam3CSK4. Cells exposed to cycloheximide are subjected to
translation inhibition that may decrease the amount of many regulatory proteins
involved in sTLR2 production and/or processing (such as a TIMP-tissue inhibitor
of metalloproteinase-), resulting in an increased processing of the membrane-
anchored TLR2. In this regard, the translation inhibitor cycloheximide inhibited
stimulated TIMP-1 production in human astrocytes or mouse osteoblastic cells
[39, 40] and basal and stimulated TIMP-1 and TIMP-2 activity [41, 42]. It is
noteworthy that ADAMs activity is regulated by multiple mechanisms [35], not
only by TIMPs, cannot be ruled out that these regulatory mechanisms are also
affected by the translation inhibitor.
Additionally, cycloheximide treatment in TLR-activated THP-1 cells leads to a
super-induction of IL-1 gene transcription. This is due to inhibition of re-
synthesis of NF-kB repressor IkB-a. IkB-a binds to the activated NF-kB in the
nucleus resulting in the inhibition of NF-kB activity [43] and this transcription
factor participates in metalloproteinase activity regulation.
Well-known activators of metalloproteinase, such as PMA and APMA [32],
decreased the content of TLR2 in the plasma membrane and increased sTLR2.
These data led us to evaluate whether TLR2 is subjected to protein ectodomain
shedding. This post-translation mechanism is highly conserved for membrane-
associated proteins of the immune system, which regulates the availability of
many molecules, such as cytokines and chemokines, among others [44].
Since production of sTLR2 is sensitive to metalloproteinase inhibitors, in
particular TAPI-1 and GI254023X and induced a decrease in soluble receptor by
activated cells, we suggest that sTLR2 production by metalloproteinase shedding is
higher in activated cells. Similar results were observed with the production of the
soluble variant of the TREM-1 receptor, where the metalloproteinase inhibitor
GM6001affects its release in LPS-stimulated monocytes [45].
As TLR2 shedding was inhibited by TAPI-1 [46], a metzincin metalloproteinase
inhibitor, the TLR2 sheddase(s) might be a member of this enzyme subfamily.
Shedding was also diminished by GI254023X, a preferential inhibitor of ADAM10,
indicating an involvement of this metalloproteinase in ligand-induced sTLR2
generation in human monocytes. ADAM10 participates in the constitutive
shedding of many substrates; such as transmembrane chemokines and adhesion
molecules [47], Notch [48] and low-affinity immunoglobulin E receptor CD23
[49]. Our results show that ADAM10 cleaves TLR2 in Pam3CSK4-activated
monocytes, establishing ADAM10 as an inducible sheddase for TLR2, as has been
also reported for IL-6R [50].
Indeed, we find sTLR2 production is decreased in both ADAM10-/- or
ADAM17-/- MEFs expressing human TLR2, suggesting that both enzymes
contribute to human TLR2 shedding in murine cells. However, in the THP-1 cell
line preferential inhibition of ADAM10 does not affect sTLR2 constitutive
production, which could be ascribed to a difference in the enzymes involved in
TLR2 Ectodomain Shedding
PLOS ONE | DOI:10.1371/journal.pone.0104624 December 22, 2014 16 / 20
TLR2 proteolytic processing in different species, such us IL-6R shedding [50].
ADAM10 and ADAM17 are important regulators of the immune system as they
are responsible for ectodomain shedding of several proteins, such as TNF-a [51]
and CX3CL1 [47]. Many substrates are processed by both enzymes; however,
other proteins are processed by either ADAM10 or ADAM17 [52]. Our results let
us to conclude that TLR2 fits in the class of substrates processed by both
proteases.
In the context of the innate immune response, shedding of TLR2 represents a
strategy by which a cell can down regulate the immune response triggered by a
microorganism or alarmins sensed by an antigen-presenting cell, a monocyte or
dendritic cell. By increasing TLR2 levels and a simultaneously decrease in
membrane TLR2 availability, an excessive inflammatory response might be
avoided. Other members of the IL1-R/TLR superfamily undergo ectodomain
shedding, such as IL-1R2 [53] and TLR9 [14]. Additionally, TLR9 is also subjected
to N-terminal domain cleavage to promote receptor activation [54]. Collectively,
our data and the other reported information suggest that proteolytic processing of
TLR contribute to regulate receptor signaling.
Due to an up-regulation of metalloproteinases in many inflammatory
disorders, high levels of sTLR2 might be produced to avoid detrimental responses.
We found that sTLR2 generated by metalloproteinase activation inhibited
Pam3CSK4-mediated IL-8 production by monocytes, suggesting that the TLR2-
shedding product is a functional negative regulator of the receptor pathway and
proteolytic processing of the receptor downregulates inflammatory signaling.
In summary, the identification of TLR2 metalloproteinase shedding as a
significant component involved in soluble receptor generation is an important
contribution to the understanding of TLR2 signaling regulation and sTLR2
pathophysiological function.
Supporting Information
S1 Fig. sTLR2 production by cells stimulated with different pro- and anti-
inflammatory molecules. (A)THP-1 cells were treated or not with Pam3CSK4
(1 mg/mL), PMA (50 ng/mL) for 5 or 18 h and then the amount of sTLR2
quantified in the cell culture supernatant by ELISA. Student t test *, p,0.05; ***,
p50.0007. (B) Isolated peripheral CD14+ cells were stimulated with Pam3CSK4
(1 mg/mL) for 18 h. Student t test *, p,0.05. (C) THP-1 cells were treated or not
with LPS (1 mg/mL) for 18 h and sTLR2 content in the cell culture supernatant
quantified by ELISA. Student t test *, p,0.05. (D) Surface TLR2 levels after
treatment of THP-1 PMA (50 ng/mL) for the indicated times. Student t test **,
p,0.01. (E) THP-1 cells were pre-treated with dexamethasone (10 nM) and
stimulated with Pam3CSK4 (1 mg/mL) for 18 hand sTLR2 content in the cell
culture supernatant quantified by ELISA.
doi:10.1371/journal.pone.0104624.s001 (TIF)
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